Marzon Tablet contains Sultamicillin tosilate 375 mg, a combination antibiotic composed of ampicillin and sulbactam in a prodrug form, designed to enhance oral bioavailability. This medication exhibits broad-spectrum antibacterial activity by inhibiting bacterial cell wall synthesis through ampicillin and overcoming beta-lactamase-mediated resistance via sulbactam, a beta-lactamase inhibitor. Marzon Tablet is indicated for the treatment of various infections caused by susceptible strains of bacteria, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections. It is particularly effective against beta-lactamase-producing organisms, which are resistant to ampicillin alone. The usual dosage and duration depend on the severity and type of infection, as well as patient-specific factors such as renal function. Marzon Tablet should be administered orally, preferably on an empty stomach to optimize absorption. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and rash. Hypersensitivity reactions to penicillins may occur and warrant immediate discontinuation and medical attention. Caution is advised in patients with a history of penicillin allergy or severe renal impairment. Marzon Tablet should be used under medical supervision, with adherence to prescribed dosage to prevent antibiotic resistance.